AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16102404 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-phase treatment (bionator, headgear/biteplane, or observation)
Number of subjects: 200
Study 16102404 — intervention group
Group type: COMPARATOR
Intervention: 2-phase treatment (full orthodontic treatment with fixed appliances after 1 year)
Number of subjects: 200
Study 12421836 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements from 4 to 9 mo
Number of subjects: 232
Study 12421836 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements [1 mg/(kg. d)] from 6 to 9 mo
Number of subjects: 232
Study 12421836 — intervention group
Group type: COMPARATOR
Intervention: Placebo from 4 to 9 mo
Number of subjects: 232
Study 10872368 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical anterior resection with bone grafting plus six months of daily isoniazid plus rifampicin (Rad6)
Number of subjects: 235
Study 10872368 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulant chemotherapy for six months with daily isoniazid plus rifampicin (Amb6)
Number of subjects: 235
Study 10872368 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulant chemotherapy for nine months with daily isoniazid plus rifampicin (Amb9)
Number of subjects: 235
Study 8557972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified antihypertensive therapy
Number of subjects: 91
Study 8557972 — intervention group
Group type: COMPARATOR
Intervention: Routine antihypertensive therapy
Number of subjects: 91
Study 1759583 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glucocorticoids
Number of subjects: 11
Study 1759583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1759583 — intervention group
Group type: EXPERIMENTAL
Intervention: Local allergen challenge
Number of subjects: 11
Study 31221882 — intervention group
Group type: EXPERIMENTAL
Intervention: Potent topical corticosteroid (TCS) once daily
Number of subjects: 0
Study 31221882 — intervention group
Group type: COMPARATOR
Intervention: Low potency topical corticosteroid (TCS) once daily
Number of subjects: 0
Study 28858136 — intervention group
Group type: EXPERIMENTAL
Intervention: SUZY curved forceps
Number of subjects: 10
Study 28858136 — intervention group
Group type: COMPARATOR
Intervention: Magill straight forceps
Number of subjects: 10
Study 26188917 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy with mitomycin C and 5‐fluorouracil
Number of subjects: 11743
Study 26188917 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 11743
Study 26188917 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemoradiotherapy
Number of subjects: 11743
Study 23478196 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with autologous bone marrow mononuclear cell transplantation (aBM‐MNC)
Number of subjects: 50
Study 23478196 — intervention group
Group type: COMPARATOR
Intervention: CABG only
Number of subjects: 50
Study 21724155 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicine for the Earth (MFTE)
Number of subjects: 58
Study 21724155 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Change Program (LCP)
Number of subjects: 58
Study 21724155 — intervention group
Group type: COMPARATOR
Intervention: Usual cardiac care (control)
Number of subjects: 58
Study 19861511 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (2 g/day)
Number of subjects: 92
Study 19861511 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (800 IU/day)
Number of subjects: 92
Study 19861511 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus Vitamin D
Number of subjects: 92
Study 19861511 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D plus Calcium
Number of subjects: 92
Study 19861511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 16710103 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy
Number of subjects: 50
Study 15622389 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 0
Study 15622389 — intervention group
Group type: EXPERIMENTAL
Intervention: Indraparinux
Number of subjects: 0
Study 15622389 — intervention group
Group type: COMPARATOR
Intervention: Standard agents
Number of subjects: 0
Study 11722712 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune milk treatment (45 g of immune milk powder twice a day for 3 months)
Number of subjects: 46
Study 11722712 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune milk treatment
Number of subjects: 46
Study 11722712 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral habit intervention only)
Number of subjects: 46
Study 9220212 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril plus conventional therapy (diuretics and digitalis)
Number of subjects: 32
Study 9220212 — intervention group
Group type: COMPARATOR
Intervention: conventional therapy (diuretics and digitalis)
Number of subjects: 32
Study 7921310 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of food records for whites in New York
Number of subjects: 872
Study 7921310 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days of food records for whites in Alabama
Number of subjects: 872
Study 3314475 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin-ampicillin
Number of subjects: 112
Study 3314475 — intervention group
Group type: COMPARATOR
Intervention: Mezlocillin
Number of subjects: 112
Study 31230020 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg melatonin per day
Number of subjects: 336
Study 31230020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 28412065 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodal Therapy (TMT)
Number of subjects: 12843
Study 28412065 — intervention group
Group type: COMPARATOR
Intervention: Radical Cystectomy (RC)
Number of subjects: 12843
Study 25476727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (abobotulinumtoxinA)
Number of subjects: 103
Study 25476727 — intervention group
Group type: COMPARATOR
Intervention: Botox (onabotulinumtoxinA)
Number of subjects: 103
Study 25476727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport
Number of subjects: 103
Study 25476727 — intervention group
Group type: COMPARATOR
Intervention: Botox
Number of subjects: 103
Study 23782529 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg b.i.d.
Number of subjects: 24
Study 23782529 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 2 mg q.d.
Number of subjects: 24
Study 21695875 — intervention group
Group type: COMPARATOR
Intervention: Liquid food intake (sweetened citronella drink) starting 6 hours after the procedure, no solid food for 24 hours.
Number of subjects: 120
Study 21695875 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid food intake resumed 6 hours after the procedure.
Number of subjects: 120
Study 20128317 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal mouthrinse 1
Number of subjects: 116
Study 20128317 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal mouthrinse 2
Number of subjects: 116
Study 20128317 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse
Number of subjects: 116
Study 20128317 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse
Number of subjects: 116
Study 16967045 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone nasal 50 microg/spray b.i.d. and Fenoxifenadine 180 mg tablets q.d.
Number of subjects: 68
Study 16967045 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl nasal drops b.i.d.
Number of subjects: 68
Study 12775344 — intervention group
Group type: EXPERIMENTAL
Intervention: Upregulated isoprenoidal pathway with increased digoxin and dolichol levels in dyslexia, developmental delay of speech milestone, and delayed recovery from global aphasia.
Number of subjects: 0
Study 12775344 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered synaptic inactivity due to changes in glycoconjugate metabolism and membrane composition.
Number of subjects: 0
Study 12775344 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemispheric chemical dominance.
Number of subjects: 0
Study 11022087 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 7
Study 11022087 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (after exclusion of Chen and McKissock trials)
Number of subjects: 7
Study 9605247 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 148
Study 9605247 — intervention group
Group type: COMPARATOR
Intervention: Bed rest alone (Control)
Number of subjects: 148
Study 8451894 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g Clindamycin (n = 79)
Number of subjects: 149
Study 8451894 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g Cefuroxim (n = 70)
Number of subjects: 149
Study 3092849 — intervention group
Group type: EXPERIMENTAL
Intervention: RO 15-1788 (benzodiazepine antagonist)
Number of subjects: 62
Study 3092849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 30390065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (Syntocinon®, Novartis; 10 puffs = 20 international units per treatment)
Number of subjects: 39
Study 30390065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 39
Study 30390065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 29122269 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected soothing music
Number of subjects: 114
Study 29122269 — intervention group
Group type: EXPERIMENTAL
Intervention: Headphone (no music)
Number of subjects: 114
Study 29122269 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 114
Study 25066651 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) for 2 hours every week for 8 weeks
Number of subjects: 44
Study 25066651 — intervention group
Group type: COMPARATOR
Intervention: Wait list (WL) control
Number of subjects: 44
Study 23615118 — intervention group
Group type: COMPARATOR
Intervention: tDCS (active)
Number of subjects: 120
Study 23615118 — intervention group
Group type: COMPARATOR
Intervention: tDCS (sham)
Number of subjects: 120
Study 23615118 — intervention group
Group type: COMPARATOR
Intervention: sertraline
Number of subjects: 120
Study 23615118 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study 22091738 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPABLE intervention (occupational therapy, nursing, handyman visits)
Number of subjects: 40
Study 22091738 — intervention group
Group type: COMPARATOR
Intervention: Attention-control visits (sedentary activities)
Number of subjects: 40
Study 19631127 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline group (0.5 mL of 1:1000 adrenaline in 500.0 mL of fortified balanced salt solution)
Number of subjects: 207
Study 19631127 — intervention group
Group type: COMPARATOR
Intervention: No-adrenaline group (no adrenaline added)
Number of subjects: 207
Study 17074540 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for UI/POP
Number of subjects: 102
Study 14987976 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal butorphanol tartrate (INB)
Number of subjects: 0
Study 14987976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11824739 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Education (SE)
Number of subjects: 12
Study 11824739 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Counseling (TC)
Number of subjects: 12
Study 11824739 — intervention group
Group type: EXPERIMENTAL
Intervention: Education with Telephone Counseling (SE+TC)
Number of subjects: 12
Study 9789647 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0
Study 7978415 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1, 1.5, and 2.5 ng/mL)
Number of subjects: 9
Study 7978415 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (above 2.5 ng/mL)
Number of subjects: 9
Study 7978415 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 to 2.25 ng/mL)
Number of subjects: 9
Study 7978415 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 9
Study 2582732 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger systolic pressure (FSP) measurement at 10 degrees C
Number of subjects: 80
Study 2582732 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS) for subjective assessment of symptoms
Number of subjects: 80
Study 2582732 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between FSP and VAS values
Number of subjects: 80
Study 1079448 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane oxygenator (MO)
Number of subjects: 91
Study 1079448 — intervention group
Group type: COMPARATOR
Intervention: Bubble oxygenator (BO)
Number of subjects: 91
Study 29273872 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole orally disintegrating (OD) tablets (30 mg) given orally once daily for 8 weeks (56 days) starting the day before ESD
Number of subjects: 304
Study 29273872 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lansoprazole (30 mg) as a continuous infusion twice daily for 3 days starting the day before ESD, followed by lansoprazole OD tablets (30 mg) orally once daily on days 4-56
Number of subjects: 304
Study 26869062 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction Osteotomy
Number of subjects: 106
Study 26869062 — intervention group
Group type: COMPARATOR
Intervention: Pie-Crust Technique
Number of subjects: 106
Study 25691686 — intervention group
Group type: EXPERIMENTAL
Intervention: rs6795970 single nucleotide polymorphism variant
Number of subjects: 225
Study 25691686 — intervention group
Group type: EXPERIMENTAL
Intervention: Common variants A1073 and P1092
Number of subjects: 225
Study 25691686 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare missense variants V94G and R1588Q
Number of subjects: 225
Study 23616513 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat rolls fortified with microencapsulated L-5-methyltetrahydrofolic acid (452 μg/d)
Number of subjects: 45
Study 23616513 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat rolls fortified with equimolar folic acid (400 μg/d)
Number of subjects: 45
Study 23616513 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no added folate)
Number of subjects: 45
Study 20693267 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of polyunsaturated fats (quartile 4)
Number of subjects: 9559
Study 20693267 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary calcium (quartile 4)
Number of subjects: 9559
Study 20693267 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient and supplement intakes (lycopene, long-chain n-3 fatty acids, vitamin D, vitamin E, selenium)
Number of subjects: 9559
Study 20693267 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of n-6 fatty acids
Number of subjects: 9559
Study 18221509 — intervention group
Group type: EXPERIMENTAL
Intervention: Teenage BCG vaccination
Number of subjects: 148
Study 18221509 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant BCG vaccination
Number of subjects: 148
Study 18221509 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 148
Study 17090740 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasterone (100-200 mg/day)
Number of subjects: 0
Study 17090740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12714124 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 86
Study 12714124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 10741631 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram pretreatment
Number of subjects: 2
Study 10741631 — intervention group
Group type: COMPARATOR
Intervention: Rifampin pretreatment
Number of subjects: 2
Study 9374251 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 50 microg/ml, one drop once daily
Number of subjects: 18
Study 9374251 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 50 microg/ml, one drop twice daily
Number of subjects: 18
Study 9374251 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 50 microg/ml, three drops once daily
Number of subjects: 18
Study 9374251 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (no treatment)
Number of subjects: 18
Study 1551961 — intervention group
Group type: EXPERIMENTAL
Intervention: Home urinary LH detection
Number of subjects: 56
Study 1551961 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical methods
Number of subjects: 56
Study 3893619 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber Band Ligation (RBL)
Number of subjects: 269
Study 3893619 — intervention group
Group type: COMPARATOR
Intervention: Phenol Injection
Number of subjects: 269
Study 3893619 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 269
Study 30985566 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight leg raise test (SLR)
Number of subjects: 14
Study 29699968 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (guided self-help)
Number of subjects: 120
Study 26048065 — intervention group
Group type: EXPERIMENTAL
Intervention: non‐emotional contingency training
Number of subjects: 62
Study 26048065 — intervention group
Group type: EXPERIMENTAL
Intervention: non‐emotional no‐contingency training
Number of subjects: 62
Study 26048065 — intervention group
Group type: COMPARATOR
Intervention: control condition
Number of subjects: 62
Study 24096053 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50mg/d
Number of subjects: 427
Study 24096053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study 24096053 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50mg/d (in patients with HAM-D17>22)
Number of subjects: 427
Study 24096053 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients with HAM-D17>22)
Number of subjects: 427
Study 24096053 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50mg/d and Placebo
Number of subjects: 427
Study 23808647 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive continuum of care intervention
Number of subjects: 0
Study 23808647 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 20530437 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone at 400 mg daily for 10 days/month for 6 months
Number of subjects: 40
Study 20530437 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study 20530437 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone
Number of subjects: 40
Study 19108019 — intervention group
Group type: EXPERIMENTAL
Intervention: PSTI + MP
Number of subjects: 33
Study 19108019 — intervention group
Group type: COMPARATOR
Intervention: IVTA
Number of subjects: 33
Study 16175516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once-daily subcutaneous injections for 5-9 days
Number of subjects: 2048
Study 14696946 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-menopausal women
Number of subjects: 45
Study 14696946 — intervention group
Group type: COMPARATOR
Intervention: Women with conservative/reactionary preference for traditional sex roles
Number of subjects: 45
Study 14696946 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal Status, Educational level and social support
Number of subjects: 45
Study 14696946 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, self-image and attitude to sex domain of the marital satisfaction scale
Number of subjects: 45
Study 14696946 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital satisfaction
Number of subjects: 45
Study 10918989 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (15 mg/day)
Number of subjects: 0
Study 10918989 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (15 mg/day)
Number of subjects: 0
Study 10918989 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene (15 mg/day)
Number of subjects: 0
Study 10918989 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 0
Study 8646707 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel treatment
Number of subjects: 77
Study 1352979 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hypotensive drugs including beta-blockers
Number of subjects: 304
Study 1352979 — intervention group
Group type: COMPARATOR
Intervention: Combination of hypotensive drugs including diuretics instead of beta-blockers
Number of subjects: 304
Study 1352979 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 304
Study 1352979 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LVMM greater than 200 g
Number of subjects: 304
Study 1352979 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression of LVH to less than 200 g
Number of subjects: 304
Study 3533137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 1200 mg/day
Number of subjects: 24
Study 3533137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3533137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg/day
Number of subjects: 24
Study 3533137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 24
Study 30259582 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mm height abutments immediately connected (Group A)
Number of subjects: 33
Study 30259582 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mm height abutments immediately connected (Group B)
Number of subjects: 33
Study 30259582 — intervention group
Group type: COMPARATOR
Intervention: 2-mm abutments inserted in a second-stage surgery (Group C)
Number of subjects: 33
Study 27566263 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib 150 mg capsule
Number of subjects: 35
Study 27566263 — intervention group
Group type: COMPARATOR
Intervention: Alectinib 20/40 mg capsules
Number of subjects: 35
Study 25349868 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min Swedish back massage for 6 weeks
Number of subjects: 90
Study 25349868 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 90
Study 22429395 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin (3.3 × 10(4) IU); n = 45
Number of subjects: 92